- ICG-001
-
- $1.00 / 1g
-
2019-12-24
- CAS:847591-62-2
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 20kg
|
| | ICG-001 Basic information |
| Product Name: | ICG-001 | | Synonyms: | ICG-001;2H-Pyrazino[1,2-a]pyriMidine-1(6H)-carboxaMide, hexahydro-6-[(4-hydroxyphenyl)Methyl]-8-(1-naphthalenylMethyl)-4,7-dioxo-N-(phenylMethyl)-, (6S,9aS)-;ICG-1;(6S,9aS)-Hexahydro-6-[(4-hydroxyphenyl)methyl]-8-(1-naphthalenylmethyl)-4,7-dioxo-N-(phenylmethyl)-2H-pyrazino[1,2-a]pyrimidine-1(6H)-carboxamide;ICG-001/ICG001;(6S,9aS)-Hexahydro-6-[(4-hydroxyphenyl)methyl]-8-(1-naphthalenylmethyl)-4,7-dioxo-N-(phenylmethyl)-2H-pyrazino[1,2-a]pyrimidine-1(6H)-carboxamide ICG001;ICG 001, >=98%;ICG-001;ICG 001;ICG001 | | CAS: | 847591-62-2 | | MF: | C33H32N4O4 | | MW: | 548.63158 | | EINECS: | | | Product Categories: | Aromatics;Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Inhibitors | | Mol File: | 847591-62-2.mol |  |
| | ICG-001 Chemical Properties |
| density | 1.37 | | storage temp. | +2C to +8C | | solubility | Soluble in DMSO (up to 50 mg/ml) or in Ethanol (up to 25 mg/ml). | | form | Off-white powder | | color | Off-white | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. |
| | ICG-001 Usage And Synthesis |
| Description | ICG-001 (847591-62-2) inhibits TCF/β-catenin mediated transcription by specifically blocking β-catenin/CBP interaction | | Uses | (S,S)-ICG 001 is a β-turn peptidomimetic molecule inhibitor of β-catenin-Tcf-mediated transcription. | | Definition | ChEBI: (6S,9aS)-6-[(4-hydroxyphenyl)methyl]-8-(1-naphthalenylmethyl)-4,7-dioxo-N-(phenylmethyl)-3,6,9,9a-tetrahydro-2H-pyrazino[1,2-a]pyrimidine-1-carboxamide is a peptide. | | General Description | A cell-permeable pyrazinopyrimidinecarboxamide that competes against β-catenin for CBP (CREB-binding protein) binding and selectively prevents CBP- but not p300-, dependent TCF/β-catenin transcriptional regulations both in cultures in vitro (5 to 25 μM) and in mice in vivo (5 mg/kg/day via osmotic pump infusion), while not affecting CBP-dependent transcriptional activities mediated by the AP-1 or CRE complex. Shown to reactivate p300//TCF/β-catenin-mediated neuronal differentiation upon NGF stimulation in PS-1 L286V mutant-expressing PC-12 cultures and be efficacious in alleviating bleomycin- (0,08 units/50 μL/mouse; administered intranasally; Cat. No. 203401) induced pulmonary fibrosis in mice. | | Biochem/physiol Actions | Cell permeable: yes | | References | 1) Emami?et al.?(2004),?A small molecule inhibitor of β-catenin/CREB-binding protein transcription;? Proc. Natl. Acad. Sci. USA,?101?12682
2) Zhou?et al.?(2012), Interactions?between β-catenin and transforming growth factor-β signaling pathways mediate epithelial-mesenchymal transition and are dependent on the transcription co-activator cAMP-response element-binding protein (CERB)-binding protein (CBP);??J. Biol. Chem.,?287?7026 |
| | ICG-001 Preparation Products And Raw materials |
|